Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 13/20 | 0.80 |
| ▸ | PLAT | P00750 | 12/20 | 0.80 |
| ▸ | F2 | P00734 | 11/20 | 0.80 |
| ▸ | PLG | P00747 | 12/20 | 0.76 |
| ▸ | F10 | P00742 | 4/20 | 0.60 |
| ▸ | KLK8 | O60259 | 3/20 | 0.60 |
| ▸ | KLK4 | Q9Y5K2 | 3/20 | 0.60 |
| ▸ | KLK2 | P20151 | 2/20 | 0.60 |
| ▸ | KLK1 | P06870 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245466 | 0.90 | PLAU (0.77) | PLAUPLATF2PLGF10 | |
| SCHEMBL2249441 | 0.89 | PLAU (1.00) | PLAUPLATF2PLGF10 | |
| SCHEMBL2245991 | 0.85 | PLAU (0.71) | PLAUPLATF2PLGF10 | |
| SCHEMBL16152328 | 0.84 | PLAU (0.69) | PLAUPLATF2PLGF10 | |
| SCHEMBL2238838 | 0.82 | PLAU (0.64) | PLAUPLATF2PLGF10 | |
| SCHEMBL2240598 | 0.81 | F2 (0.80) | PLAUPLATF2PLGF10 | |
| SCHEMBL13736064 | 0.81 | PLAU (0.67) | PLAUPLATF2PLGF10 | |
| SCHEMBL7403534 | 0.81 | F2 (0.86) | PLAUPLATF2PLGF10 | |
| SCHEMBL14377755 | 0.79 | F2 (0.59) | PLAUPLATF2PLGF10 | |
| Trifluoroacetic Acid SCHEMBL13736749 | 0.79 | PLAU (0.64) | PLAUPLATF2PLGF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940856-B1 | NOVEL UROKINASE INHIBITORS | UNIV ANTWERPEN (BE) | 2014-10-08 | — | — | EP | disclosed |
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
| EP-1940856-A1 | NOVEL UROKINASE INHIBITORS | Universiteit Antwerpen (BE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045496-A1 | NOVEL UROKINASE INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312191-A1 | Novel Urokinase Inhibitors | PLAU, PLAUR, SERPINE1 | PLAU 1/4885PLAT 5/4885F2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.